Ahead of this week's PDUFA date for ipilimumab in second-line metastatic melanoma, the drug hit its endpoint in the first-line setting, as Bristol-Myers Squibb Co.'s 2009 buyout of Medarex Inc. for $2.4 billion just keeps looking better and better.